Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Name / Ticker | Price | Zen Rating |
---|---|---|
$46.01 | A | |
$8.19 | A | |
$63.31 | A |